[This material was presented as part of Epstein Becker Green’s Counsel to Counsel Roundtable on Monday, May 4, 2026. Co-presenters were Professor Kathleen M. Boozang and Professor David Obderbeck of Seton Hall School of Law.]
In 2026, several federal cases are poised to shape regulatory risk, reimbursement, and False Claims Act exposure, as well as innovation pathways across the health care and life sciences sectors. These include cases decided in 2024 and 2025 that continue to have ongoing impacts, as well as more recent cases involving cutting-edge technology. This article highlights five cases to monitor (or their progeny), why these cases matter to in-house legal teams, and practical steps for health care and life sciences general counsel (GC) to consider.
Blog Editors
Recent Updates
- Five Cases Health Care and Life Sciences GCs Should Keep Watching in 2026
- Protecting Purchased Goodwill: Sale-of-Business Restrictive Covenants Under National Scrutiny
- Watch: How to Protect Your Business from a Counterparty's Financial Crisis – Speaking of Litigation
- First DOJ DEI False Claims Act Investigation Settlement Fetches $17 Million
- DOJ Creates National Fraud Enforcement Division: What It Means for Fraud Enforcement in America